AB 40. Six minute walking test and DLCO for non-small cell lung cancer. Easy performed tests in every day practice
Abstract

AB 40. Six minute walking test and DLCO for non-small cell lung cancer. Easy performed tests in every day practice

Paul Zarogoulidis1, Theodora Kerenidi2, Theodoros Kontakiotis1, Ourania Tremma1 , Konstantinos Porpodis1, Anastasios Kallianos3, Ageliki Rapti3, Christoforos Foroulis4, Athanasios Zissimopoulos5, Nikolaos Courcoutsakis6, Kosmas Tsakiridis7, Efi Mylwnaki1, Konstantinos Zarogoulidis1

1Pulmonary Department, “G. Papanikolaou” General Hospital, Aristotle University of Thessaloniki, Greece; 2Pulmonary Department, University of Thessali, Greece; 32nd Pulmonology Clinic, Hospital of Chest Diseases “SOTIRIA” , Athens, Greece; 4Thoracic and Cardiovascular Surgery Department, AHEPA University Hospital, Thessaloniki, Greece; 5Nuclear Medicine Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Greece; 6Radiology Department, University General Hospital of Alexandroupolis, Democritus University of Thrace, Greece; 7Cardiothoracic Department, “Saint Luke” Private Hospital, Thessaloniki, Greece

Background: Several studies have demonstrated that reduced lung function is a significant risk factor for lung cancer and increase surgical risk in patients with operable stages of lung cancer. The aim of the study was to perform pulmonary function tests and investigate which is a favorable respiratory function test for overall survival between lung cancer stages.

Methods: Lung function tests were performed to lung cancer patients with non-small cell lung cancer of stage I, II, III and IV (241 patients in total). They had the last follow-up consecutively between December 2006 and July 2008. The staging was decided according to the sixth edition of TNM classification of NSCLC. The Forced Expiratory Volume in 1sec (FEV1), Forced Vital Capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) were measured according to American Thoracic Society/European Respiratory Society guidelines. The 6 Minute Walking Test (6MWT) was measured according to the American Thoracic Society.

Results: There was a significant association of the DLCO upon diagnosis and overall survival for stage II (P<0.007) and IV (P<0.003). Furthermore, there was a significant association between 6MWT and overall survival for stage III (P<0.001) and stage IV (P<0.010).

Conclusions: The significance for each lung function test is different among the stages of NSCLC. DLCO and 6MWT upon admission are the most valuable prognostic factors for overall survival of NSCLC.

Cite this abstract as: Zarogoulidis P, Kerenidi T, Kontakiotis T, Tremma O, Porpodis K, Kallianos A, Rapti A, Foroulis C, Zissimopoulos A, Courcoutsakis N, Tsakiridis K, Mylwnaki E, Zarogoulidis K. Six minute walking test and DLCO for non-small cell lung cancer. Easy performed tests in every day practice. J Thorac Dis 2012;4(S1):AB40. DOI: 10.3978/j.issn.2072-1439.2012.s040

Article Options

Download Citation

Share